Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · DYN · as of Jun 8, 2026
Activity summary
Buy transactions
7
P-Purchase only
Sell transactions
76
12 Months
Buy/Sell ratio
0.09
Buy/Sell (by trades)
Overall sentiment
Dyne Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
DYN insider buying and selling by quarter
DYN insider selling · DYN insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · DYN ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
DYN executive sell shares · DYN board member insider trading · DYN insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | Posner Brian S Director | Purchase | 2,500 | $44K | Form 4 |
| May 26, 2026 | Posner Brian S Director | Purchase | 2,000 | $36K | Form 4 |
| May 20, 2026 | Posner Brian S Director | Purchase | 2,500 | $43K | Form 4 |
| May 13, 2026 | Friedl-Naderer Johanna Chief Commercial Officer | Sale | 228 | $4K | Form 4 |
| May 13, 2026 | Kerr Douglas Chief Medical Officer | Sale | 1,564 | $29K | Form 4 |
| May 13, 2026 | Lucera Erick CFO | Sale | 1,448 | $27K | Form 4 |
| May 13, 2026 | Cox John CEO & President · Director | Sale | 3,311 | $61K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 6,241 | $112K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 6,081 | $110K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 43,621 | $793K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 3,136 | $56K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 3,056 | $55K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 21,926 | $399K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 2,466 | $44K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 2,403 | $43K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 17,244 | $313K | Form 4 |
| May 4, 2026 | Rhodes Jason P Director | Sale | 61 | $1K | Form 4 |
| May 5, 2026 | Rhodes Jason P Director | Sale | 60 | $1K | Form 4 |
| May 6, 2026 | Rhodes Jason P Director | Sale | 428 | $8K | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 119,115 | $2.19M⚡ | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 52 | $988 | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 59,870 | $1.10M⚡ | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 26 | $494 | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 47,082 | $865K | Form 4 |
| Apr 28, 2026 | Rhodes Jason P Director | Sale | 21 | $399 | Form 4 |
Friedl-Naderer Johanna
Chief Commercial Officer
Date
May 13
Shares
228
Price
$18.36
Value
$4K
Kerr Douglas
Chief Medical Officer
Date
May 13
Shares
1,564
Price
$18.36
Value
$29K
Cox John
CEO & President · Director
Date
May 13
Shares
3,311
Price
$18.36
Value
$61K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About DYN insider trading
DYN insider trades
Dyne Therapeutics, Inc. (DYN) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Rhodes Jason P (Director), Kersten Dirk (Director), Cox John (CEO & President · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. DYN insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Dyne Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
DYN insider trading · 5 questionsThe insiders of Dyne Therapeutics, Inc. (DYN) include executives and directors such as Rhodes Jason P (Director), Kersten Dirk (Director), Cox John (CEO & President · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026